OR WAIT 15 SECS
The Massachusetts Biotechnology Council (MassBio) released its 2018 Industry Snapshot report, in partnership with EvaluatePharma, which shows Massachusetts biotechs accounting for nearly half of all US-based biotech IPOs (48%), up from 30% in 2016.
The report shows that 2018 has already surpassed 2017 in terms of total Massachusetts IPOs at 15, which accounts for nearly 40% of all US-based biotech IPOs (January – July 2018).
Job growth in the Massachusetts biopharma industry remains strong, with consistent 4-5% increases in the last few years, and nearly 30% growth over the last decade (28% from 2008 – 2017). Massachusetts also continues to attract a greater share of public funding, with:
To download the full report, visit here.